Aberrant splicing in human cancer: An RNA structural code point of view
Frontiers in Pharmacology · 23.02.2023 · 14
DOI: 10.3389/fphar.2023.1137154 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 23.02.2023. Verfasst von Maria Apostolidi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Agilent Laboratories, Agilent Technologies, Santa Clara, CA, United States. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agilent Technologies.
Abstract (Originalsprache)
Alternative splicing represents an essential process that occurs widely in eukaryotes. In humans, most genes undergo alternative splicing to ensure transcriptome and proteome diversity reflecting their functional complexity. Over the last decade, aberrantly spliced transcripts due to mutations in cis - or trans -acting splicing regulators have been tightly associated with cancer development, largely drawing scientific attention. Although a plethora of single proteins, ribonucleoproteins, complexed RNAs, and short RNA sequences have emerged as nodal contributors to the splicing cascade, the role of RNA secondary structures in warranting splicing fidelity has been underestimated. Recent studies have leveraged the establishment of novel high-throughput methodologies and bioinformatic tools to shed light on an additional layer of splicing regulation in the context of RNA structural elements. This short review focuses on the most recent available data on splicing mechanism regulation on the basis of RNA secondary structure, emphasizing the importance of the complex RNA G-quadruplex structures (rG4s), and other specific RNA motifs identified as splicing silencers or enhancers. Moreover, it intends to provide knowledge on newly established techniques that allow the identification of RNA structural elements and highlight the potential to develop new RNA-oriented therapeutic strategies against cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Agilent Laboratories, Agilent Technologies, Santa Clara, CA, United States.
- Department of Biochemistry, School of Medicine, University of Patras, Patras, Greece.
Förderung
- Agilent Technologies
Zitieren
APA
Apostolidi, M., & Stamatopoulou, V. (2023). Aberrant splicing in human cancer: An RNA structural code point of view. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1137154
Vancouver
Apostolidi M, Stamatopoulou V. Aberrant splicing in human cancer: An RNA structural code point of view. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1137154
BibTeX
@article{Apostolidi2023,
author = {Apostolidi, Maria and Stamatopoulou, Vassiliki},
title = {Aberrant splicing in human cancer: An RNA structural code point of view},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1137154}
}
EUVIMED